Silo Pharma, Inc.
No enriched coverage for $SILO in the last 7 days.
No SEC Form 4 filings for $SILO in the last 30 days.
See all $SILO insider activity →Indonesia Stock Exchange (IDX) expanded its High Shareholding Concentration (HSC) list to 51 stocks, adding names including DCII, BYAN, and MORA. The HSC label highlights concentrated ownership and potential liquidity and price sensitivity risks. IDX cited updated methodology and noted regulators are assessing liquidity quality ahead of MSCI review in Nov 2026.
Silo Pharma (Nasdaq: SILO) said its wholly owned subsidiary QwikAgents was accepted into AMD’s AI Developer Program, gaining access to AMD Developer Cloud credits, tools, and training resources. QwikAgents is developing an enterprise AI agent platform with starter plans from $14 per month, targeting deployment, testing, optimization, benchmarking, and potential training of agent workloads.
Silo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029760202ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 9, 2026, between Silo Pharma, Inc., a Nevada corporation (the “ Company ”), and each purcha
Recent SILO coverage spans corporate actions, technology and regulation.
SILO’s HSC status can raise liquidity risk premium and potentially reduce marginal buyers.
Program acceptance may improve QwikAgents’ AI agent development and hosting capacity, but it is not a quantified revenue or clinical milestone.
The filing signals a new capital-raising or securities issuance transaction, which can dilute holders and change near-term funding risk.
The dilutive equity/warrant financing is likely to pressure SILO shares near-term, while providing roughly $4M gross proceeds.
The dilutive financing and warrant structure likely pressures near-term valuation, while providing limited runway via about $4M upfront and up to $7.7M if warrants are exercised.
alphai scores every news story that mentions SILO with an AI model for sentiment and relevance, and aggregates insider trades from Silo Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Indonesia Stock Exchange (IDX) expanded its High Shareholding Concentration (HSC) list to 51 stocks, adding names including DCII, BYAN, and MORA. The HSC label highlights concentrated ownership and potential liquidity and price sensitivity risks. IDX cited updated methodology and noted regulators are assessing liquidity quality ahead of MSCI review in Nov 2026.
4 min readSilo Pharma (Nasdaq: SILO) said its wholly owned subsidiary QwikAgents was accepted into AMD’s AI Developer Program, gaining access to AMD Developer Cloud credits, tools, and training resources. QwikAgents is developing an enterprise AI agent platform with starter plans from $14 per month, targeting deployment, testing, optimization, benchmarking, and potential training of agent workloads.
3 min readSilo Pharma, Inc. (SILO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029760202ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 9, 2026, between Silo Pharma, Inc., a Nevada corporation (the “ Company ”), and each purcha
3 min readSilo Pharma (NASDAQ: SILO) said it entered definitive agreements for a private placement at-the-market under NASDAQ rules to issue and sell 619,965 shares, or pre-funded warrants, plus Series A-3 and short-term Series A-4 warrants. Price was $6.452 per share, with $6.21 exercise price. Gross proceeds are about $4 million, up to $7.7 million if warrants are fully exercised.
2 min readSilo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.
4 min readSilo Pharma (Nasdaq: SILO) announced a private placement priced at-the-market under Nasdaq rules for 619,965 shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to buy up to 619,965 shares each. Price is $6.452 per share, with $6.21 warrant exercise. Gross proceeds are about $4M upfront, up to $7.7M if warrants are fully exercised in cash. Net proceeds for working capital and general corporate purposes.
3 min readU.S. stock index futures were mixed premarket on Friday, with S&P 500 futures flat and Nasdaq 100 futures down 0.3% by 08:25 ET. CCC Intelligent Solutions rose 14.5% on a Reuters report it is exploring a sale with Morgan Stanley. Circle gained 7% after OCC approval for a digital currency bank. Meta rose 3.8% on a new AI model. Fermi America fell 14.6% after pricing $375m convertible notes, and Silo Pharma dropped 22% on an up to $11.7m ATM placement.
3 min readSilo Pharma (NASDAQ:SILO) shares dropped 22% after the company announced an up to $11.7 million private placement under Nasdaq rules. It plans to issue 619,965 shares plus Series A-3 and A-4 warrants for up to 619,965 shares each at $6.452 per share. Expected gross proceeds are about $4 million upfront, with up to about $7.7 million more if warrants are exercised.
4 min readCertara said it is integrating Nvidia’s BioNeMo Agent Toolkit into its AI drug development platform, adding agentic frameworks to support tasks across dosing optimization, clinical-data analysis, ADMET evaluation and regulatory evidence. Silo Pharma’s subsidiary QwikAgents joined Nvidia’s Developer Program to expand its autonomous AI agent platform. NVDA shares were up; Certara and Silo were down at publication.
4 min readSilo Pharma (Nasdaq: SILO) said it hired Resyca to run a drug-device robustness study for SPC-15, its intranasal nose-to-brain PTSD prophylactic using a microchip-based nasal spray. The 30-day study will assess device performance and formulation stability to support a planned FDA Type C meeting request on IND strategy and Phase 1 design.
4 min read
